These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1480832)

  • 1. [Electrophysiologic study of cibenzoline in patients with paroxysmal atrial fibrillation with special reference to atrial fibrillation threshold].
    Inoue D; Ishibashi K; Sakai R; Inoue M; Omori I; Asayama J; Nakagawa M
    Kokyu To Junkan; 1992 Dec; 40(12):1203-8. PubMed ID: 1480832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of cibenzoline on atrial vulnerability and value of electrophysiological methods in the treatment of paroxysmal atrial fibrillation].
    Kühlkamp V; Ickrath O; Seipel L
    Z Kardiol; 1990 Aug; 79(8):541-6. PubMed ID: 2220012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of pilsicainide hydrochloride on atrial fibrillation threshold].
    Ishibashi K; Inoue D; Omori I; Shirayama T; Inoue M; Sakai R; Yamahara Y; Asayama J; Nakagawa M
    Kokyu To Junkan; 1993 Aug; 41(8):763-7. PubMed ID: 8351435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of cibenzoline in the termination and long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset].
    Komatsu T; Nakamura S; Kimura M; Owada S; Saito E; Kobayashi T; Okumura K
    J Cardiol; 2001 Feb; 37(2):75-82. PubMed ID: 11255698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiological determinants of atrial fibrillation in sinus node dysfunction despite atrial pacing.
    De Sisti A; Attuel P; Manot S; Fiorello P; Halimi F; Leclercq JF
    Europace; 2000 Oct; 2(4):304-11. PubMed ID: 11194597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of the efficacy and tolerability of oral administration of cibenzoline in the prevention of recurrence of symptomatic atrial fibrillation].
    Medvedowsky JL; Bine-Scheck F; Dambrine P; Domerego JJ; Garnier LF; Labaki F; Piechaczyk P; Rouesnel P; Schenowitz A
    Ann Cardiol Angeiol (Paris); 1994 Feb; 43(2):89-96. PubMed ID: 8172484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term prevention of the recurrence of auricular fibrillation using cibenzoline. Multicenter study apropos of 89 case reports].
    Frances Y; Luccioni R; Delaage M; Donnarel G; Medvedowsky JL; Quiret JC
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():99-103. PubMed ID: 3938266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cibenzoline: electrophysiologic effects of a new class I anti-arrhythmia agents in supraventricular tachycardia].
    Pfitzner P; Manz M; Schütz R; Lüderitz B
    Z Kardiol; 1989 Oct; 78(10):654-60. PubMed ID: 2686252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of sotalol hydrochloride therapy on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
    Telichowski A; Banasiak W; Wiech K; Zeborowski J; Pieróg M; Ponikowski P; Kałka D; Lacheta W; Fuglewicz A; Telichowski C
    Pol Merkur Lekarski; 1996 Nov; 1(5):303-9. PubMed ID: 9273201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial cardioversion by class IC Drugs during 4 months of persistent atrial fibrillation in the goat.
    Eijsbouts S; Ausma J; Blaauw Y; Schotten U; Duytschaever M; Allessie MA
    J Cardiovasc Electrophysiol; 2006 Jun; 17(6):648-54. PubMed ID: 16836716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sick sinus syndrome with and without atrial fibrillation: atrial refractoriness and conduction characteristics.
    De Sisti A; Leclercq JF; Fiorello P; Di Lorenzo M; Manot S; Halimi F; Attuel P
    Cardiologia; 1999 Apr; 44(4):361-7. PubMed ID: 10371788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between long-term preventive efficacy of cibenzoline and atrial natriuretic peptide in patients with paroxysmal atrial fibrillation].
    Komatsu T; Nakamura S; Kimura M; Owada S; Yomogida K; Kameda K; Oikawa K; Tomita H; Okumura K
    J Cardiol; 2002 Feb; 39(2):93-9. PubMed ID: 11873440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic effects and efficacy of cibenzoline on stimulation-induced atrial fibrillation and flutter and implications for treatment of paroxysmal atrial fibrillation.
    Kühlkamp V; Meerhof J; Schmidt F; Mayer F; Ickrath O; Haasis R; Seipel L
    Am J Cardiol; 1990 Mar; 65(9):628-32. PubMed ID: 2309633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias].
    Maison-Blanche P; Brembilla-Perrot B; Fauchier JP; Babuty D; Garnier LF; Rouesnel P; Breuillac JC; Funck F; Scheck F; Peraudeau P; Medvedowsky JL
    Ann Cardiol Angeiol (Paris); 1997 Feb; 46(2):109-16. PubMed ID: 9137677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the efficacies of disopyramide, cibenzoline and aprindine for the termination of paroxysmal and persistent atrial fibrillation in elderly and non-elderly patients].
    Komatsu T; Nakamura S; Suzuki O; Yomogida K; Horiuchi D; Abe N; Kameda K; Owada S; Tomita H; Oikawa K; Okumura K
    J Cardiol; 2003 Apr; 41(4):191-8. PubMed ID: 12728540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of cibenzoline administration for vagally mediated paroxysmal atrial fibrillation using frequency-domain heart rate variability analysis.
    Miyakoshi M; Ikeda T; Miwa Y; Sakaki K; Ishiguro H; Abe A; Tsukada T; Mera H; Yusu S; Yoshino H
    J Cardiol; 2009 Aug; 54(1):86-92. PubMed ID: 19632526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-arrhythmia and pro-arrhythmia effects of oral cibenzoline therapy in sustained ventricular tachycardia].
    Hoffmann E; Bach P; Haberl R; Mattke S; Steinbeck G
    Z Kardiol; 1992 Jul; 81(7):378-84. PubMed ID: 1509795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Electrophysiologic properties of cibenzoline in Wolff-Parkinson-White syndrome and atrioventricular nodal reentry tachycardia].
    Kühlkamp V; Ickrath O; Schmid F; Mayer F; Haasis R; Seipel L
    Z Kardiol; 1989 Oct; 78(10):640-6. PubMed ID: 2686251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of cibenzoline in the preventive treatment of recurrent atrial arrhythmia].
    Pisapia A; Bine-Scheck F; Schenowitz A; Domerego JJ; Maraud L; Canler A; Labban N; Viart R; Aubry P; Beruben E
    Ann Cardiol Angeiol (Paris); 1994 Mar; 43(3):143-51. PubMed ID: 7912916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.